Brief

"On Tuesday, December 10, 2024, the National Institutes of Health (NIH) issued an update regarding NIH Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution or Pain. The study, called STOMP, found that tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox, although it was safe and had no safety concerns."

This content is restricted.

Highlights content goes here...

This content is restricted.

National Institutes of Health (NIH)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies